STOCK TITAN

Trevi Therapeutics, Inc. - TRVI STOCK NEWS

Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a late-stage biopharmaceutical company devoted to addressing chronic pruritic conditions and chronic cough through its investigational therapy, Haduvio™ (oral nalbuphine ER). Haduvio is an oral extended-release formulation of nalbuphine, a synthetic opioid with a dual mechanism of action: as a ĸ-opioid receptor agonist and µ-opioid receptor antagonist. This unique mechanism has shown promise in clinical trials for reducing symptoms associated with chronic cough, particularly in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, a dermatologic condition characterized by pruriginous lesions.

Trevi is advancing various pruritic conditions through clinical development, including prurigo nodularis, which currently has no approved therapies in the US or EU. The company's lead indication involves extensive studies and trials, such as the recent Phase 2b/3 PRISM (Pruritus Relief through Itch-Scratch Modulation) trial, which demonstrated Haduvio's efficacy and safety over 52 weeks.

In the chronic cough segment, Trevi's Haduvio is undergoing trials like the Phase 2a RIVER study for RCC and the Phase 2b CORAL trial for chronic cough in IPF. The RIVER trial is a double-blind, placebo-controlled study evaluating Haduvio's impact on 24-hour cough frequency, while the CORAL trial investigates three dose levels of Haduvio against a placebo in IPF patients, assessing endpoints like cough frequency reduction and quality of life improvements.

Trevi's innovative approach aims to provide relief where current treatments fail, supported by promising clinical data and ongoing trials. The company's commitment to addressing unmet medical needs is reflected in its thorough and transparent communication with investors and stakeholders, ensuring that all developments are promptly shared, including financial results and future plans.

For more detailed information on Trevi Therapeutics, its clinical trials, and its forward-looking statements, visit TreviTherapeutics.com and follow the company on Twitter and LinkedIn.

Rhea-AI Summary

Trevi Therapeutics plans to present its investigational therapy Haduvio™ at two major investor conferences in February 2023. The BIO CEO & Investor Conference will take place from February 6-9, with Trevi’s presentation scheduled for February 7 at 10:45 a.m. ET. The SVB Securities Global Biopharma Conference follows from February 13-16, where a presentation is set for February 14 at 11:20 a.m. ET. Trevi Therapeutics, trading under the symbol TRVI, is developing Haduvio for chronic cough and prurigo nodularis, having reported promising Phase 2 trial results for chronic cough in patients with idiopathic pulmonary fibrosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.17%
Tags
conferences
-
Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced significant business updates on Jan. 5, 2023, highlighting the progression of its investigational therapy, Haduvio™. Aiming to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis, Trevi is preparing for several clinical studies in 2023, including a Phase 2 dose-ranging study and a Phase 1b respiratory physiology study. The company is also conducting a human abuse liability study and will request an End-of-Phase 2 meeting with the FDA. Trevi will participate in key conferences starting January 9, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
conferences
-
Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) will present at the Biotech Showcase 2023 on January 10, 2023, at 3:00 p.m. PT. This event coincides with the 12th Annual LifeSci Partners Corporate Access Event, held from January 9-11, 2023, in San Francisco, CA. Trevi is focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough and prurigo nodularis. Positive results from the Phase 2 CANAL trial for chronic cough related to idiopathic pulmonary fibrosis have prompted Trevi to prioritize further clinical development in this area.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
conferences
Rhea-AI Summary

Trevi Therapeutics has appointed David Clark, MD, MRCP, as the new Chief Medical Officer to advance the development of Haduvio™, an oral investigational therapy for chronic cough related to idiopathic pulmonary fibrosis. Dr. Clark brings over 25 years of experience in clinical development and has previously led clinical teams at several biopharmaceutical companies. He will play a critical role in executing Trevi's clinical strategies, supported by the insights from prior CMO Thomas Sciascia, who transitions to Chief Science Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.91%
Tags
management
-
Rhea-AI Summary

Trevi Therapeutics (TRVI) reported its Q3 2022 financial results, highlighting a net loss of $8.3 million, up from $7.3 million year-over-year, largely due to increased R&D expenses of $5.8 million. The clinical-stage biopharmaceutical firm announced significant progress in its Phase 2 CANAL trial for Haduvio, showing a 75.1% reduction in cough frequency in IPF patients, backed by statistically significant data. Trevi ended the quarter with approximately $126 million in cash and equivalents, poised to fund further development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced participation in the Stifel 2022 Healthcare Conference on November 16, 2022, from 3:35 p.m. to 4:05 p.m. EDT. CEO Jennifer Good and CFO Lisa Delfini will be present for a fireside chat discussing their investigational therapy Haduvio™ for chronic cough. A live audio webcast will be available on their website, with an archive accessible post-event. Trevi focuses on developing Haduvio, which has shown positive results in Phase 2 trials for chronic cough associated with idiopathic pulmonary fibrosis (IPF).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences
Rhea-AI Summary

Trevi Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on November 10, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and provide a corporate update. The focus will be on its investigational therapy, Haduvio, for chronic cough conditions. The company has completed a Phase 2 trial for Haduvio's efficacy in treating chronic cough linked to idiopathic pulmonary fibrosis (IPF) and aims to target further development in chronic cough conditions including IPF and refractory chronic cough.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
conferences earnings
-
Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced statistically significant data from its Phase 2 CANAL trial of Haduvio (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF). The trial demonstrated a 76.1% reduction in 24-hour cough frequency for nalbuphine ER subjects versus 25.3% for placebo (p<0.0001). Key secondary endpoints also showed significant improvement. The results will be presented at the British Thoracic Society's Winter Meeting in London on November 23, 2022. Chronic cough affects over a million patients globally, highlighting the importance of effective treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.56%
Tags
none
Rhea-AI Summary

Trevi Therapeutics announced the pricing of its underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $50 million. The offering is led by SVB Securities, Stifel, and Oppenheimer & Co. and expected to close on September [__], 2022, pending customary conditions. The shares are sold under a shelf registration statement filed with the SEC. Trevi’s investigational therapy, Haduvio, addresses chronic cough in idiopathic pulmonary fibrosis and prurigo nodularis, with the offering intended to bolster its clinical development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.56%
Tags

FAQ

What is the current stock price of Trevi Therapeutics (TRVI)?

The current stock price of Trevi Therapeutics (TRVI) is $4.05 as of December 20, 2024.

What is the market cap of Trevi Therapeutics (TRVI)?

The market cap of Trevi Therapeutics (TRVI) is approximately 379.4M.

What is Trevi Therapeutics, Inc.?

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for chronic pruritic conditions and chronic cough, including prurigo nodularis and idiopathic pulmonary fibrosis (IPF).

What is Haduvio?

Haduvio (oral nalbuphine ER) is Trevi Therapeutics' investigational therapy designed to treat chronic cough and pruritic conditions, leveraging a dual mechanism of action.

What are the primary conditions Trevi Therapeutics is targeting?

Trevi focuses on chronic pruritic conditions, such as prurigo nodularis, and chronic cough conditions, including chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

What are the latest clinical trials conducted by Trevi Therapeutics?

Recent trials include the Phase 2b/3 PRISM trial for prurigo nodularis, Phase 2a RIVER trial for refractory chronic cough, and the Phase 2b CORAL trial for chronic cough in IPF.

Has Haduvio been proven effective?

Clinical trials, such as the PRISM and CANAL trials, have shown promising results, indicating Haduvio's potential in reducing chronic cough and pruritic symptoms.

Are there any approved therapies for the conditions Trevi Therapeutics is addressing?

Currently, there are no approved therapies for prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis (IPF) in the US or EU. Trevi aims to fill this gap with Haduvio.

What are the next steps for Trevi Therapeutics in their clinical trials?

Trevi plans to analyze the data from ongoing trials, such as the RIVER and CORAL studies, and prepare for discussions with regulatory authorities regarding the next phases of development.

Where can investors find more information about Trevi Therapeutics?

Investors can visit Trevi's official website at www.TreviTherapeutics.com and follow the company on social media platforms like Twitter and LinkedIn.

What financial results were reported by Trevi Therapeutics in the latest quarter?

In the latest quarter, Trevi reported increased R&D expenses due to clinical trial costs, stable G&A expenses, and a controlled net loss in line with ongoing development activities.

How does Trevi Therapeutics ensure communication with its stakeholders?

Trevi maintains transparent communication through regular updates on its website, press releases, and participation in industry conferences and investor calls.

Trevi Therapeutics, Inc.

Nasdaq:TRVI

TRVI Rankings

TRVI Stock Data

379.36M
65.16M
1.18%
80.61%
2.28%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW HAVEN